Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study.
Ariel IsraelEugene MerzonAlejandro A SchäfferYotam ShenharIlan GreenAvivit Golan CohenEytan RuppinEli MagenShlomo VinkerPublished in: BMJ (Clinical research ed.) (2021)
In this large population of adults tested for SARS-CoV-2 by RT-PCR after two doses of mRNA BNT162b2 vaccine, a gradual increase in the risk of infection was seen for individuals who received their second vaccine dose after at least 90 days.